Study guide
13.3 Dark-Adapted (Scotopic) Testing: Rod-Driven Responses & Combined Maximal Response
IJCAHPO Certified Ophthalmic Medical Technologist COMT
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The COMT Examination, Eligibility & Certification Requirements
1.1 The 190-Question Multiple-Choice Examination & the 22 Official Content Areas 1.2 The COT Skill Evaluation & the COMT Performance Test 1.3 Eligibility Pathways, Fees, Timelines & Recertification
2 Chapter 2: General Medical Knowledge I — Ocular Anatomy & Physiology
2.1 Orbit, Eyelids, Lacrimal System, Conjunctiva & Extraocular Muscles 2.2 Cornea, Sclera, Anterior Chamber, Angle, Aqueous Dynamics & Crystalline Lens 2.3 Uvea, Retina, Vitreous, Optic Nerve, Ocular Circulation & the Visual Pathway
3 Chapter 3: General Medical Knowledge II — Eye Disease, Systemic Manifestations, Terminology & Safety
3.1 Frequently Encountered Eye Conditions by Structure & Inflammation Versus Infection 3.2 Body Systems & the Ocular Manifestations of Systemic Disease 3.3 Medical Terminology, Approved Abbreviations, Hazardous Waste & Clinic Safety
4 Chapter 4: Ophthalmic History Taking & Clinical Documentation
4.1 The Five History Domains: Ocular, Medical, Medication, Social & Family 4.2 Charting Conventions, Scribing & the Electronic Medical Record
5 Chapter 5: Visual Assessment, Accommodative Testing & Low Vision
5.1 Measuring Acuity at Every Level & in Preliterate, Illiterate and Non-Verbal Patients 5.2 Stereoacuity, Near Point of Accommodation, Near Point of Convergence & the AC/A Ratio 5.3 Low Vision Assessment, Magnification Calculation & Device Instruction
6 Chapter 6: Tonometry, Keratometry & Pupil Measurement
6.1 Goldmann Applanation Tonometry: Technique, Sources of Error & the Imbert-Fick Principle 6.2 Hand-Held Applanators, Non-Contact Tonometry, Rebound Tonometry & Disinfection 6.3 Manual & Automated Keratometry: Technique, Readings and Interpretation 6.4 Pupil Measurement, Shape, Reactivity & Evaluating Anisocoria
7 Chapter 7: Lensometry, Spectacle Optics & Prescription Analysis
7.1 Manual Lensometry: Eyepiece Focus, Neutralising Sphere, Cylinder & Axis 7.2 Neutralising Reading Adds: Bifocal, Trifocal, Progressive & Determining the Near Add 7.3 Identifying & Measuring Prism: Ground-In, Decentration, Fresnel Press-On & Slab-Off 7.4 Transposition, Spherical Equivalent, Vertex Distance & Prescription Components 7.5 The Geneva Lens Clock, Lens Materials, Progressive Markings & Spectacle Adjustment
8 Chapter 8: Refraction, Retinoscopy & Refinement
8.1 Autorefraction, Refractive Error Types & Establishing an Objective Starting Point 8.2 Streak Retinoscopy: With Motion, Against Motion, Neutralisation & Working Distance 8.3 Subjective Refinement: Fogging, Jackson Cross Cylinder, Duochrome & Binocular Balance 8.4 Near Add Determination, Vertex Recording & Refraction in Difficult Situations
9 Chapter 9: Ocular Motility, Strabismus & Advanced Optics
9.1 Ocular Kinematics: Ductions, Versions, Vergences, Hering's & Sherrington's Laws 9.2 Quantitative Strabismus Measurements: Alternate Cover Test, Prism Cover Test & Lancaster Red-Green / Hess Screen 9.3 Cranial Nerve Palsies (CN III, IV, VI), Restrictive Myopathies & Forced Duction Testing 9.4 Clinical Optics, Prentice's Rule, Slab-Off Prisms & Wavefront Aberrations
10 Chapter 10: Sensory Fusion Testing, Nystagmus, Amblyopia & Vergence Therapy
10.1 Sensory Fusion Testing: Worth 4-Dot, Maddox Rod & Bagolini Lenses 10.2 Hirschberg, Krimsky, Brückner & Fusional Vergence Amplitudes 10.3 Nystagmus, Amblyopia Therapy & Convergence Training
11 Chapter 11: Advanced Visual Fields & Neuro-Ophthalmic Evaluation
11.1 Amsler Grid & Confrontation Visual Field Testing 11.2 Automated Static Perimetry: HFA Strategies (SITA Standard, SITA Fast), Reliability Indices & Statpac Analysis 11.3 Visual Field Defect Patterns: Glaucomatous Nerve Fiber Bundle Deficits vs. Retinal Pathology 11.4 Kinetic Perimetry (Goldmann Perimetry) & Neurological Visual Pathway Defect Localization 11.5 Pupillary Pathways, RAPD Quantitation with Neutral Density Filters & Pharmacologic Testing
12 Chapter 12: Supplemental Testing — Glare, PAM, Colour Vision, Tear Film & Slit Lamp Technique
12.1 Glare Testing, Potential Acuity Meter & Contrast Sensitivity 12.2 Colour Vision: Pseudoisochromatic Plates, Farnsworth-Munsell D-15 & the 100-Hue Test 12.3 Tear Film Assessment: Schirmer, Tear Break-Up Time, Vital Dyes & Corneal Sensitivity 12.4 Slit Lamp Technique, Slit Lamp Lenses, Direct Ophthalmoscopy & Pen Light Examination 12.5 Exophthalmometry, Head & Posture Assessment and Wavefront Diagnostics
13 Chapter 13: Full-Field Electroretinography & ISCEV Protocols
13.1 Retinal Neurophysiology & Electrophysiologic Origin of Waveforms 13.2 ISCEV Standard Full-Field ERG Protocol & Electrode Systems 13.3 Dark-Adapted (Scotopic) Testing: Rod-Driven Responses & Combined Maximal Response 13.4 Light-Adapted (Photopic) Testing: Cone Response, 30-Hz Flicker & Oscillatory Potentials
14 Chapter 14: Advanced Electrophysiologic Testing (mfERG, PERG, VEP, EOG)
14.1 Multifocal Electroretinogram (mfERG): Topographic Retinal Mapping 14.2 Pattern Electroretinogram (PERG): Ganglion Cell & Macular Function 14.3 Visual Evoked Potentials (VEP): Flash, Pattern & Visual Pathway Integrity 14.4 Electrooculogram (EOG), Arden Ratio & RPE Light Peak Dynamics
15 Chapter 15: Fluorescein Angiography Principles & Technique
15.1 Fluorescein Angiography Principles, Exciter/Barrier Filters & Injection Protocol 15.2 Normal Transit Phases & Retinal/Choroidal Circulation Hemodynamics 15.3 Adverse Reactions, Patient Safety & Emergency Management
16 Chapter 16: Angiographic Interpretation & Pathology
16.1 Hyperfluorescence Mechanisms: Leakage, Staining, Pooling, Window Defects & Autofluorescence 16.2 Hypofluorescence Mechanisms: Vascular Non-Perfusion & Blocking Defects 16.3 Indocyanine Green (ICG) Angiography: Principles, Indications & Choroidal Pathology
17 Chapter 17: Advanced Fundus Imaging & Optical Coherence Tomography
17.1 Fundus Autofluorescence (FAF) & Ultra-Widefield Fundus Imaging 17.2 Spectral-Domain and Swept-Source OCT: Retinal Layer Architecture & Quantitative Analysis 17.3 Enhanced Depth Imaging (EDI-OCT) & Anterior Segment OCT (AS-OCT) 17.4 Optical Coherence Tomography Angiography (OCTA): Chorioretinal Plexuses & Biomarkers
18 Chapter 18: Ophthalmic Photography & Videography
18.1 The Fundus Camera: Optics, Alignment & Correcting Artefacts 18.2 Standard Fundus Photography: ETDRS Fields, Stereo Pairs, Red-Free & Wide-Field Imaging 18.3 Slit Lamp & Anterior Segment Photography 18.4 External Photography, Nine-Gaze Motility Documentation & Image Management
19 Chapter 19: Ophthalmic Echography (A-Scan, B-Scan & UBM)
19.1 Physics of Ophthalmic Ultrasound, Acoustic Impedance & Probe Transducers 19.2 Standardized Diagnostic A-Scan: Acoustic Spikes, Tissue Reflectivity & Attenuation 19.3 Diagnostic B-Scan Echography: Topographic, Kinetic & Quantitative Vitreoretinal Evaluation 19.4 Ultrasound Biomicroscopy (UBM): Anterior Segment Anatomy, Angle Pathology & Ciliary Body Imaging
20 Chapter 20: Biometry, Topography & Corneal Analysis
20.1 Optical Biometry vs. Immersion/Contact Ultrasound Biometry 20.2 Intraocular Lens (IOL) Power Calculation Formulas & Post-Refractive Adjustments 20.3 Corneal Topography, Scheimpflug Tomography & Keratoconus Screening 20.4 Corneal Pachymetry, Endothelial Specular Microscopy & Anterior Chamber Depth
21 Chapter 21: Rigid Gas Permeable & Specialty Lens Fitting
21.1 Rigid Gas Permeable (RGP) Material Properties, Dk/t & Oxygen Permeability 21.2 RGP Base Curve Selection, Diagnostic Fitting & Fluorescein Pattern Evaluation 21.3 Scleral Contact Lens Design, Sagittal Depth Fitting & Clearance Evaluation 21.4 Keratoconus, Irregular Corneas & Hybrid Contact Lens Systems
22 Chapter 22: Toric, Multifocal, Therapeutic Lenses & Complications
22.1 Toric Soft Contact Lens Dynamics, Stabilization Techniques & LARS Rule 22.2 Presbyopic & Multifocal Contact Lens Systems: Simultaneous vs. Translating Designs 22.3 Therapeutic Bandage Contact Lenses, Amniotic Membranes & Orthokeratology 22.4 Contact Lens-Induced Pathology, Giant Papillary Conjunctivitis & Infectious Keratitis
23 Chapter 23: Ocular Pharmacology
23.1 Routes of Drug Delivery, Prescription Components & Instillation Technique 23.2 Mydriatics, Cycloplegics, Anaesthetics & Diagnostic Agents 23.3 Glaucoma Medications: Classes, Mechanisms & Side Effects 23.4 Anti-Infectives, Corticosteroids, NSAIDs, Allergy Agents, Lubricants, Supplements & Anti-VEGF
24 Chapter 24: Microbiology & Ocular Specimen Collection
24.1 Types of Microorganisms & Pathways of Disease Transmission 24.2 Assisting with Conjunctival & Corneal Specimen Collection
25 Chapter 25: Anterior Segment, Glaucoma & Refractive Surgery
25.1 Advanced Phacoemulsification, Surgical Steps, Fluidics & Complication Management 25.2 Premium Intraocular Lenses: Toric, Multifocal, EDOF & Lens Exchange 25.3 Glaucoma Surgical Procedures: Trabeculectomy, Aqueous Shunts & MIGS Devices 25.4 Laser In Situ Keratomileusis (LASIK), PRK, SMILE & Phakic IOLs
26 Chapter 26: Vitreoretinal, Corneal & Trauma Surgery
26.1 Pars Plana Vitrectomy (PPV), Scleral Buckling & Intraocular Tamponades (Gas/Silicone Oil) 26.2 Corneal Transplantation: Penetrating Keratoplasty (PKP) & Lamellar Keratoplasty (DSAEK, DMEK, DALK) 26.3 Ocular Trauma Repair: Open Globe Management, Hyphema, Vitreous Loss & Endophthalmitis Protocol
27 Chapter 27: Surgical Asepsis, Instrumentation & Laser Procedures
27.1 Operating Room Sterilization, Aseptic Field Maintenance & Universal Precautions 27.2 Microsurgical Instrumentation, Maintenance & Sharps Safety 27.3 Ophthalmic Laser Physics, Delivery Systems & Safety (Nd:YAG, Argon/FD-Nd:YAG, SLT)
28 Chapter 28: Ophthalmic Patient Services & Education
28.1 Communicating with Patients, Families and Colleagues, and Handling Dissatisfaction 28.2 Patient Education & Counselling on Conditions, Medications, Tests and Results 28.3 Ophthalmic Emergencies, First Aid, Vital Signs & CPR 28.4 Triage, Urgency-Based Scheduling, Patient Flow & Telephone Management 28.5 Dressings and Shields, Prosthetics, Legal Forms, Referrals & Reimbursement Support
29 Chapter 29: Clinic Operations — Equipment Maintenance, Ethics, Coding & Compliance
29.1 Equipment Maintenance, Calibration, Emergency Equipment & Inventory 29.2 Confidentiality, Informed Consent, Scope of Practice & Ethical Standards 29.3 Coding, Scribing Compliance, Quality Assurance & Regulatory Requirements
13.3 Dark-Adapted (Scotopic) Testing: Rod-Driven Responses & Combined Maximal Response
Key Takeaways Explain This Topic AI
Dark adaptation for a minimum of 20 minutes (optimally 30 minutes) in absolute darkness is required to achieve greater than 90% to 95% rod rhodopsin regeneration.
The Dark-Adapted 0.01 ERG (0.01 cd·s·m⁻²) selectively isolates the rod pathway below cone threshold, producing a slow, rounded b-wave (implicit time 50–100 ms) with no discernible a-wave.
The Dark-Adapted 3.0 ERG (3.0 cd·s·m⁻²) evokes the combined maximal rod-cone response, dominated by rods (75–80%), producing a prominent negative a-wave and high b-wave with a normal b-to-a ratio greater than 1.5.
The Dark-Adapted 10.0 ERG (10.0 cd·s·m⁻²) drives saturated photoreceptor hyperpolarization, permitting clear separation of the a-wave trough from the ascending b-wave and modeling of rod phototransduction kinetics.
Classic retinitis pigmentosa (RP) characteristically abolishes the DA 0.01 rod ERG early in the disease course, whereas complete congenital stationary night blindness (CSNB1) preserves the DA 3.0 a-wave while extinguishing the b-wave.
Last updated: September 2026
Dark-Adapted (Scotopic) Testing: Rod-Driven Responses & Combined Maximal Response
Core Clinical Mandate: Scotopic electroretinography assesses the integrity of the rod photoreceptors and their downstream depolarizing ON-bipolar pathways. Because rods outnumber cones across the human retina by approximately 20 to 1 (~120 million rods vs. ~6 million cones), dark-adapted responses constitute the largest voltage deflections recorded during full-field ERG testing.
1. Biophysics of Dark Adaptation and the Visual Cycle
To evaluate the rod system without cone interference, the retina must be transitioned into a state of maximal scotopic sensitivity.
Kinetics of the Dark Adaptation Curve
Following exposure to bleaching light, human visual threshold recovery follows a classic biphasic dark adaptation curve (the Kohlrausch curve):
First Phase (Cone Limb): Rapid threshold decrease occurring over the first 5 to 8 minutes . Cones regenerate their photopigments rapidly, reaching their maximum sensitivity plateau.
The Rod-Cone Break (Kohlrausch Bend): Occurs at approximately 7 to 10 minutes of darkness, when the recovering sensitivity of rods overtakes that of cones.
Second Phase (Rod Limb): Slower, prolonged sensitivity recovery continuing for 20 to 30 minutes , reflecting the slow enzymatic resynthesis of rhodopsin. Dark Adaptation Kinetics:
- Threshold | [Initial Bleach]
- | \ (Cone Phase: 0-8 min)
- | \___
- | \ (Rod-Cone Break: 7-10 min)
- | \ (Rod Phase: 10-30 min)
- |__________\_________________ (Rod Plateau)
- 0 5 10 15 20 25 30 Time (min)
- The Retinoid (Visual) Cycle
Resynthesis of rhodopsin requires enzymatic recycling of all-trans-retinal back into 11-cis-retinal through the retinal pigment epithelium (RPE) :
Following photoisomerization in the rod outer segment, all-trans-retinal is reduced to all-trans-retinol by all-trans-retinol dehydrogenase ( RDH8/RDH12 ).
All-trans-retinol is transported across the subretinal space bound to interphotoreceptor retinoid-binding protein ( IRBP ) and enters the RPE.
Inside the RPE, lecithin retinol acyltransferase ( LRAT ) esterifies it into all-trans-retinyl esters.
The key isomerohydrolase RPE65 cleaves and isomerizes all-trans-retinyl ester into 11-cis-retinol .
Finally, 11-cis-retinol dehydrogenase ( RDH5 ) oxidizes it to 11-cis-retinal , which is exported back to the photoreceptor outer segment to conjugate with opsin apoprotein, reforming active rhodopsin .
ISCEV Dark Adaptation Rules
Duration: A minimum of 20 minutes in absolute, light-tight darkness is mandatory. For definitive diagnostic evaluations of inherited retinal degenerations or night blindness, 30 minutes is strongly recommended.
Dim Red Light Precautions: Although rod photoreceptors have negligible spectral sensitivity to wavelengths longer than 650 nm, exposure to red light must be kept strictly to a minimum during electrode placement. Bright or prolonged red illumination can still bleach rods and reset dark adaptation.
2. Dark-Adapted 0.01 ERG (Scotopic Dim-Flash Rod Response)
The Dark-Adapted 0.01 ERG (formerly designated the "rod response") is designed to evaluate rod pathway function in complete isolation from the cone system.
Stimulus Specifications & Isolation Mechanics
Stimulus Flash Strength: 0.01 c d ⋅ s ⋅ m − 2 cd\cdot s\cdot m^{-2} c d ⋅ s ⋅ m − 2 (dim white flash, approximately 2.5 log units below the standard 3.0 flash).
Physiological Isolation: Cone photoreceptors have a significantly higher activation threshold than rods. A 0.01 c d ⋅ s ⋅ m − 2 cd\cdot s\cdot m^{-2} c d ⋅ s ⋅ m − 2 flash is approximately 1.5 to 2.0 log units below the electrical threshold of cones . Therefore, cones do not respond at all to this stimulus, yielding a 100% rod-driven response.
Waveform Morphology and Generators
No Discernible a-Wave: The hyperpolarization of individual rod outer segments to such a dim flash is too small to summate into a visible extracellular a-wave at the cornea.
Solitary, Rounded b-Wave: The dim flash signal is amplified through the high-gain rod-to-rod bipolar synapse in the outer plexiform layer. Depolarization of hundreds of thousands of rod ON-bipolar cells produces a broad, smooth, positive b-wave.
Amplitude: Typically 100 to 300 μ V \mu\text{V} μ V (with contact lens electrodes).
Implicit Time: Markedly prolonged, ranging between 50 and 100 milliseconds . The sluggish kinetics reflect the slow enzymatic cascade of rod phototransduction and the high-convergence architecture of the rod pathway (where 20–30 rods pool into a single rod bipolar cell). DA 0.01 Waveform Profile:
- [Baseline 0 µV] -----------------\ /---
- \ / (Broad, slow b-wave, ~70-90 ms)
- \_____/
- (No a-wave)
- 3. Dark-Adapted 3.0 ERG (Combined Rod-Cone Maximal Response)
The Dark-Adapted 3.0 ERG (formerly known as the "standard combined response" or "maximal response") is elicited by presenting the standard ISCEV flash to the dark-adapted eye.
Stimulus Specifications & Cellular Contributions
Stimulus Flash Strength: 3.0 c d ⋅ s ⋅ m − 2 cd\cdot s\cdot m^{-2} c d ⋅ s ⋅ m − 2 (standard flash, unattenuated white light).
Co-activation: Because this flash is far above the threshold for both rods and cones, it simultaneously activates:
The entire dark-adapted rod system (rods and rod ON-bipolar cells).
The dark-adapted cone system (cones, cone ON-bipolars, and cone OFF-bipolars).
Relative Contributions: Rods account for approximately 75% to 80% of the total b-wave amplitude, while cones contribute the remaining 20% to 25% .
Waveform Morphology and Dynamics
Prominent Negative a-Wave: Driven by the simultaneous, rapid hyperpolarization of millions of rod outer segments, with a smaller contribution (~20%) from cone outer segments. The slope of the leading edge of the a-wave reflects the biochemical gain of the phototransduction cascade.
High-Amplitude b-Wave: Arises from the massive, synchronous depolarization of rod ON-bipolar and cone ON-bipolar cells.
Amplitudes: Highest voltage recorded in clinical electroretinography. a-wave amplitude typically ranges from 150 to 350 μ V \mu\text{V} μ V ; b-wave amplitude ranges from 350 to 700 μ V \mu\text{V} μ V (using contact lens electrodes).
Implicit Times: Much faster than the dim-flash rod response. a-wave implicit time is 15 to 20 ms ; b-wave implicit time is 35 to 50 ms .
The b-to-a Ratio ( b / a b/a b / a Ratio)
The b / a b/a b / a amplitude ratio on the DA 3.0 response is a primary clinical metric for assessing inner vs. outer retinal disease: Ratio = b-wave amplitude (measured from a-wave trough to b-wave peak) a-wave amplitude (measured from baseline to a-wave trough) \text{Ratio} = \frac{\text{b-wave amplitude (measured from a-wave trough to b-wave peak)}}{\text{a-wave amplitude (measured from baseline to a-wave trough)}} Ratio = a-wave amplitude (measured from baseline to a-wave trough) b-wave amplitude (measured from a-wave trough to b-wave peak)
Normal Range: > 1.5 > 1.5 > 1.5 (typically 1.6 to 2.5 in healthy eyes).
Subnormal Ratio ( < 1.2 < 1.2 < 1.2 ): Suggests inner retinal compromise.
Electronegative Ratio ( < 1.0 < 1.0 < 1.0 ): Indicates selective middle/inner retinal transmission loss (bipolar signaling defect or central retinal artery ischemia) with preserved outer retinal photoreceptors.
4. Dark-Adapted 10.0 ERG (Strong-Flash Response)
In 2015, ISCEV formally added the Dark-Adapted 10.0 ERG as a standard protocol (utilizing a 10.0 c d ⋅ s ⋅ m − 2 cd\cdot s\cdot m^{-2} c d ⋅ s ⋅ m − 2 flash):
Photoreceptor Saturation: A 10.0 c d ⋅ s ⋅ m − 2 cd\cdot s\cdot m^{-2} c d ⋅ s ⋅ m − 2 flash drives all rod photoreceptors to their maximum hyperpolarization ( R m p 3 R_{mp3} R m p 3 ). This produces a saturated, crisper a-wave trough that clearly separates the photoreceptor response from the onset of the ascending b-wave.
Biophysical Modeling: Allows mathematically rigorous modeling of the leading edge of the a-wave using the Lamb-Pugh / Hood-Birch formulation , calculating the amplification constant ( S S S ) and maximum saturated response ( R m a x R_{max} R ma x ) of rod phototransduction.
Overcoming Media Opacities: In patients with dense mature cataracts, vitreous hemorrhage, or corneal edema that scatter and absorb light, the 10.0 c d ⋅ s ⋅ m − 2 cd\cdot s\cdot m^{-2} c d ⋅ s ⋅ m − 2 flash delivers sufficient photons to the retina to differentiate between true retinal degeneration and simple optical obstruction.
5. Clinical Correlations & Diagnostic Patterns
Condition DA 0.01 Rod ERG DA 3.0 a-Wave DA 3.0 b-Wave b / a b/a b / a Ratio Clinical & Genetic Hallmarks
Retinitis Pigmentosa (RP) Extinguished early Severely reduced & delayed Severely reduced & delayed Normal to reduced ( > 1.0 >1.0 > 1.0 ) Night blindness (nyctalopia), bone-spicule pigment, visual field constriction
Complete CSNB (CSNB1) Extinguished Normal Severely Reduced < 0.5 (Electronegative) NYX , GRM6 , TRPM1 mutations; ON-bipolar transmission failure
Incomplete CSNB (CSNB2) Subnormal (residual) Moderately reduced Subnormal < 1.0 (Variable) CACNA1F mutations; presynaptic L-type C a 2 + Ca^{2+} C a 2 + channel defect
X-Linked Retinoschisis Normal to subnormal Normal Reduced < 1.0 (Electronegative) RS1 gene; foveal & peripheral schisis splitting inner nuclear layer
Vitamin A Deficiency Extinguished Reduced Severely reduced Variable Malnutrition, bariatric surgery, Bitot spots; completely reversible
Fundus Albipunctatus Extinguished at 20 min Reduced at 20 min Reduced at 20 min Normal RDH5 gene; normalizes after 2–4 hours of prolonged dark adaptation